YHLO News
中文版 English
News
News > YHLO News
Raise Global Awareness of Rheumatoid Arthritis
      Date:2019-10-12


Today is World Arthritis Day, which was established by the Arthritis and Rheumatism International (ARI) in 1996. There are over 100 types of arthritis, and the most common forms are osteoarthritis and rheumatoid arthritis.


Facts about RA
Rheumatoid Arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. Unlike the osteoarthritis, the most common form of arthritis, RA is a systemic disease which can affect body systems, such as the cardiovascular or respiratory systems. The damage to the associated organs caused by RA could lead to severe conditions such as lung fibrosis, pleuritis, pericarditis, scleritis, rheumatoid nodules, vasculitis and Sicca syndrome etc. 

Epidemiology
RA affects about 24.5 million people as of 2015 and it is reported that in 40% of RA patients cannot work permanently within 5 years and their life expectancy is shortened by 3 to 14 years.

Diagnosis
RA requires early diagnosis, and early treatment can prevent future deformity and disability, and will likely help reduce collateral damage, such as atherosclerosis. 

ACR (American College of Rheumatology) has made diagnostic criteria for RA serologically:
High-positive RF or high-positive ACPA (CCP)
Elevated ESR or CRP value

YHLO provides total solution for the serological detection of RA with iFlash CLIA system and Vision ESR analyzer include:
RF (IgGM): High sensitivity
RF IgM: High sensitivity
RF IgG: High sensitivity
Anti-RA33: Early screening and risk prediction
Anti-CCP: High specificity
CRP: Joint inflammation marker

CopyRight@2019 Shenzhen YHLO Biotech Co., Ltd. rights reserved
Headquarter: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
Int'l Business Office: Rm.501, Building A1, Kexing Science Park, No.15 Keyuan Road, Nanshan District, 518057 Shenzhen, P.R.China
Tel: +86 755 26601910   /   Fax: +86 755 26473319   /   Email: marketing@szyhlo.com

About YHLONewsProductsServicesJoin UsInvestor RelationsContact Us